Leveraging Adeno-Associated Viruses (AAVs) in therapeutic approaches for monogenic neurological diseases

Supplied by PerkinElmer on Wednesday, 07 September, 2022


Within the field of neurological diseases, there is great interest in looking at rare diseases of monogenic origin with the hope of developing disease-modifying gene therapies, as opposed to treatments for symptom management. Therefore, using relatively tunable systems like recombinant AAVs, scientists are also exploring in vivo gene delivery in parallel to ex vivo.

Learn about key strategies and innovations in this space that are enabling advanced gene therapy.


Related White Papers

What you need to know at a glance

Discover this original infographic for in-depth...

[eBook] The 21st century lab: your roadmap for transformation

Reinventing laboratory informatics to accelerate...

Limit your risk, avoid waste and ensure compliance to government legislation

This paper provides an overview of the importance...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd